TABLE 1.
Pre-transplantation demographic and clinical characteristics of study cohort, stratified by number of induction courses before CR achievement
| All (n=220) | 1 Induction Course (n=138) | 2 Induction Courses (n=66) | >2 Induction Courses (n=16) | P-value | |
|---|---|---|---|---|---|
| Median Age at HCT (range), years | 51.9 (18.2-75.0) | 51.5 (18.2-75.0) | 51.9 (20.2-73.7) | 61.1 (18.2-67.3) | 0.22 |
| Male Gender | 57.3% | 50.0% | 66.7% | 81.3% | 0.01 |
| Median WBC at Diagnosis, ×103/μL | 5.0 (0.2-280) | 4.2 (0.3-238) | 5.7 (0.2-280) | 34.9 (0.6-145) | 0.31 |
| Cytogenetics | 0.40 | ||||
| Favorable | 4.6% | 6.5% | 1.5% | 0% | |
| Intermediate | 67.3% | 67.4% | 65.2% | 75.0% | |
| Adverse | 25.0% | 22.5% | 31.8% | 18.8% | |
| Missing | 3.2% | 3.6% | 1.5% | 6.3% | |
| Secondary AML | 37.7% | 42.0% | 30.3% | 31.3% | 0.25 |
| Consolidation Therapy | <0.001 | ||||
| No | 16.8% | 10.9% | 16.7% | 68.8% | |
| Yes (HiDAC-containing) | 70.9% | 74.6% | 75.8% | 18.8% | |
| Yes (not HiDAC-containing) | 12.3% | 14.5% | 7.6% | 12.5% | |
| Median CR Duration before HCT (range), days | 116 (16-788) | 121 (22-788) | 120 (26-465) | 59 (16-231) | 0.0014 |
| Recovered Peripheral Blood Counts before HCT* | 84.1% | 87.7% | 83.3% | 56.3% | 0.009 |
| Routine Cytogenetics before HCT | 0.23 | ||||
| Normalized karyotype | 48.2% | 50.7% | 45.5% | 37.5% | |
| Abnormal karyotype | 11.4% | 8.0% | 18.2% | 12.5% | |
| Missing/non-informative data | 40.5% | 41.3% | 36.4% | 50.0% | |
| HCT Comorbidity Index | 0.73 | ||||
| 0 | 15.0% | 13.0% | 19.7% | 12.5% | |
| 1-2 | 31.8% | 30.4% | 34.9% | 31.3% | |
| ≥3 | 52.7% | 55.8% | 45.5% | 56.3% | |
| Missing | 0.5% | 0.7% | 0% | 0% | |
| MRDpos at HCT by MFC | 19.6% | 16.7% | 22.7% | 31.3% | 0.24 |
| Myeloablative Conditioning | 68.6% | 67.4% | 75.8% | 50.0% | 0.12 |
| Unrelated Donor | 61.8% | 63.0% | 60.6% | 56.3% | 0.82 |
| Median Donor Age (range), years | 40.1 (18.1-76.6) | 40.1 (18.1-71.5) | 38.6 (18.6-76.6) | 43.7 (20.2-71.8) | 0.55 |
| HLA-Matching | 0.32 | ||||
| Matched/identical | 81.4% | 82.6% | 80.3% | 75.0% | |
| 1 locus mismatch | 16.8% | 16.7% | 15.2% | 25.0% | |
| ≥2 loci mismatch | 1.8% | 0.7% | 4.6% | -- | |
| Conditioning Regimen | |||||
| L-TBI ± Flu or Clo | 31.4% | 32.6% | 24.2% | 50.0% | |
| Bu/Cy ± L-TBI | 26.4% | 24.6% | 33.3% | 12.5% | |
| Bu/Flu | 14.1% | 15.9% | 12.1% | 6.3% | |
| H-TBI/Cy or H-TBI/Tepa/Flu | 7.3% | 3.6% | 10.6% | 25.0% | |
| Treo/Flu ± L-TBI | 18.6% | 21.7% | 15.2% | 6.3% | |
| Flu/Radiolabeled Ab/L-TBI ± Cy | 2.3% | 1.4% | 4.5% | 0% | |
| Source of Stem Cells | 0.07 | ||||
| PBSC | 81.4% | 84.1% | 72.7% | 93.8 | |
| BM | 18.6% | 15.9% | 27.3% | 6.3 | |
| GVHD Prophylaxis | |||||
| Calcineurin Inhibitor + Methotrexate | 55.5% | 54.3% | 59.1% | 50.0% | |
| Calcineurin Inhibitor + MMF | 32.3% | 32.6% | 27.3% | 50.0% | |
| Cy ± Calcineurin Inhibitor | 9.5% | 9.4% | 12.1% | 0% | |
| Other | 2.7% | 3.6% | 1.5% | 0% |
*
ANC ≥1,000/μL and platelets ≥100,000/μL Abbreviations: Ab, antibody; BM, bone marrow; Bu, busulfan; Clo, clofarabine; Cy, cyclophosphamide; Flu, fludarabine; H-TBI, high-dose total body irradiation; HCT, hematopoietic cell transplantation; HiDAC, high-dose cytarabine; L-TBI, low-dose total body irradiation; MFC, multiparameter flow cytometry; MMF, mycophenolate mofetil; PBSC, peripheral blood stem cells; Tepa; thiotepa; Treo, treosulfan